Comparative Pharmacology
Head-to-head clinical analysis: DUEXIS versus KETOPROFEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DUEXIS versus KETOPROFEN.
DUEXIS vs KETOPROFEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DUEXIS is a combination of ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, and famotidine, a histamine H2-receptor antagonist that decreases gastric acid secretion. Famotidine mitigates the risk of NSAID-induced gastric ulcers.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis; also inhibits leukotriene synthesis and has direct membrane-stabilizing effects.
One tablet (800 mg ibuprofen/26.6 mg famotidine) orally three times daily.
Oral: 75 mg three times daily or 50 mg four times daily; maximum 300 mg/day. Intravenous: 100 mg every 12-24 hours, infused over 15-30 minutes.
None Documented
None Documented
Clinical Note
moderateKetoprofen + Gatifloxacin
"Ketoprofen may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderateKetoprofen + Rosoxacin
"Ketoprofen may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderateKetoprofen + Levofloxacin
"Ketoprofen may increase the neuroexcitatory activities of Levofloxacin."
Clinical Note
moderateKetoprofen + Trovafloxacin
"Ketoprofen may increase the neuroexcitatory activities of Trovafloxacin."
Ibuprofen: 2-4 hours (terminal); requires every 6-8 hour dosing. Famotidine: 2.5-3.5 hours (normal renal function); prolonged to 20 hours or more in severe renal impairment (CrCl < 30 mL/min).
Terminal elimination half-life: 2-4 hours; clinical context: short half-life allows for quick drug clearance but requires frequent dosing; may be prolonged in elderly or renal impairment.
Ibuprofen: ~1% unchanged in urine, 14% as conjugated metabolites, remainder as oxidative metabolites; <1% excreted in feces. Famotidine: 65-70% unchanged in urine, 30-35% metabolized hepatic; <10% fecal.
Renal: ~80% (60% as glucuronide conjugates, 20% as unchanged drug); Biliary/Fecal: ~20% via bile.
Category C
Category D/X
NSAID/H2 Antagonist Combination
NSAID